MODY (Maturity-Onset Diabetes of the Young)

USMLE Step 1 trap: Misclassifies MODY inheritance as autosomal recessive rather than autosomal dominant. MODY follows autosomal dominant inheritance; a single mutated allele in a gene regulating beta-cell function (e.g., GCK, HNF1A) is sufficient to cause disease.

MODY is a group of monogenic diabetes syndromes that USMLE Step 1 tests in two main ways: recognizing the clinical scenario (young, non-obese, multi-generational family history, no autoimmune markers) and knowing gene-specific management. Students consistently make two errors — assuming MODY is autosomal recessive because it involves enzyme or transcription factor defects, and defaulting to insulin for any non-T2DM young patient, missing that HNF1A-MODY responds dramatically to sulfonylureas. MODY is autosomal dominant, presents before age 25, and is cleanly distinct from both T1DM and T2DM.

The tricky part is that MODY gets lumped mentally with either T1DM (because it's young and lean) or T2DM (because it's not autoimmune). Neither is right. The two highest-yield subtypes are GCK-MODY (MODY2) — a glucokinase mutation that resets the glucose threshold, causing mild stable fasting hyperglycemia — and HNF1A-MODY (MODY3) — a transcription factor mutation causing progressive insulin deficiency that responds beautifully to sulfonylureas. These two subtypes behave completely differently and require different management, which is exactly the kind of distinction USMLE Step 1 loves to exploit.

Students consistently miss two things: they assume MODY is autosomal recessive (because they associate enzyme/metabolic defects with recessive inheritance), and they default to insulin for any non-T2DM diabetes, missing that HNF1A-MODY is actually better managed with sulfonylureas. If you see a multi-generational family with diabetes, young age of onset, no obesity, and no antibodies, MODY should jump to the top of your differential — and then you need to know which subtype dictates which treatment.

Common misconceptions

Common mistake

Wrong: MODY follows autosomal recessive inheritance like many metabolic enzyme deficiencies.

Right: MODY follows autosomal dominant inheritance; a single mutated allele in a gene regulating beta-cell function (e.g., GCK, HNF1A) is sufficient to cause disease.

MODY is autosomal dominant, not recessive — a single mutated allele in a beta-cell regulatory gene (GCK, HNF1A, etc.) is sufficient to disrupt function and cause disease. The confusion comes from associating enzyme defects with recessive inheritance, but MODY genes are transcription factors or metabolic sensors where haploinsufficiency (losing one functional copy) is enough to break the system. The clinical tell is multi-generational, vertical transmission in the family tree — exactly what you'd expect from dominant inheritance.

Common mistake

Wrong: All MODY subtypes require insulin therapy similar to T1DM.

Right: HNF1A-MODY (MODY3) is exquisitely sensitive to sulfonylureas because the defect is in transcription factor-driven beta-cell function, not autoimmune destruction, making sulfonylureas more effective than insulin in these patients.

HNF1A-MODY is not autoimmune and beta cells are structurally intact but functionally impaired at the transcription level — sulfonylureas bypass that defect by directly stimulating insulin secretion via the KATP channel, making these patients far more responsive than typical T2DM patients. Defaulting to insulin is a common error because the patient is young and non-obese (looks like T1DM), but the absence of autoimmune markers and the dominant family history point to MODY3, where sulfonylureas are not just acceptable but actually superior to insulin.

Common mistake

Gap: Missing that GCK-MODY causes benign mild hyperglycemia that usually does not require treatment

GCK-MODY (MODY2) causes a stable, mild fasting hyperglycemia due to a reset glucose threshold and typically requires no pharmacologic treatment because complications are rare.

In GCK-MODY, the glucokinase mutation raises the glucose threshold at which beta cells sense and respond to glucose, so the body simply 'thinks' a higher glucose level is normal. The result is mild, non-progressive fasting hyperglycemia (typically 100–145 mg/dL) that has been stable since birth. Because this represents a resetting of the setpoint rather than progressive beta-cell destruction, microvascular complications are rare, and treatment with medication does not meaningfully change outcomes — so the answer on the exam is: no pharmacologic treatment needed.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Know the defining features of MODY: autosomal dominant inheritance, onset before age 25, non-obese patient, absent autoimmune markers (no anti-GAD, no anti-islet antibodies), and a positive multi-generational family history.
Recognize that HNF1A-MODY (MODY3) should be treated with sulfonylureas as first-line rather than insulin, because the defect is in transcription factor-regulated beta-cell function — not autoimmune destruction — making these patients exquisitely sulfonylurea-sensitive.
Understand that GCK-MODY (MODY2) causes a mild, stable fasting hyperglycemia due to a reset glucose sensing threshold and typically requires no pharmacologic treatment because vascular complications are rare.

Can you avoid these mistakes?

A 19-year-old non-obese woman is found to have fasting glucose of 118 mg/dL on routine labs. Her mother and maternal grandfather both have 'mild diabetes' that was never treated with medications. Anti-GAD antibodies are negative. What is the most likely diagnosis, and what is the appropriate management?

A 22-year-old man is diagnosed with diabetes. He has no obesity, no autoimmune markers, and his father and paternal grandmother both had diabetes diagnosed before age 30. Genetic testing shows an HNF1A mutation. What is the first-line pharmacologic treatment, and why is it preferred over insulin in this patient?

Why does MODY follow autosomal dominant rather than autosomal recessive inheritance, and what clinical feature in the family history should make you suspect dominant transmission?

A patient with known GCK-MODY (MODY2) asks whether they need to start metformin or insulin to prevent diabetic complications. How do you counsel them, and what is the pathophysiologic reason for your answer?

MODY (Maturity-Onset Diabetes of the Young)

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics